Anticancer agents can impair ovarian function, resulting in premature menopause and
associated long-term health effects. Ovarian toxicity is not usually adequately assessed in …

The treatment of ovarian cancer is set to undergo rapid changes, as strategies incorporating
molecular targeted therapies begin to take shape. These are based on a better appreciation …

Over the past two decades, empirical optimization of cytotoxic chemotherapy combinations
and surgical debulking procedures have improved outcomes and survival in epithelial …

Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of
recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of …

One of the major issues in the 3rd Ovarian Cancer Consensus Conference (OCCC) was to
achieve consensus among study groups worldwide on appropriate requirements for entry …

Antiangiogenic agents have demonstrated improved progression-free survival in women
with primary and recurrent epithelial ovarian cancer (EOC). Biomarkers that predict …

Background Therapy for advanced epithelial ovarian cancer (OC) includes first line
platinum/taxane-containing chemotherapy and re-treatment with platinum-containing …

Because most patients presenting with advanced ovarian cancer are not curable by surgery
alone, chemotherapy represents an essential component of treatment. The disease may be …

Over the past several years, clinical research efforts in ovarian cancer employing a number
of US Food and Drug Administration (FDA)-approved antineoplastic agents have permitted …

Late and recurrent stage ovarian cancer has a high mortality and low response rate to
therapy beyond first line treatment. Although first line platinum/taxane based regimens have …